Serum Amphiregulin Differentiates Acute GI GVHD from Infectious Colitis

Key Points

• Acute gastrointestinal graft-versus-host disease can be differentiated effectively using serum amphiregulin levels, highlighting its potential as a biomarker.
• Key evidence shows that higher amphiregulin levels correspond to cases of acute GI GVHD compared to infectious colitis, thus aiding diagnosis.
• Observational analysis utilized serum amphiregulin measurements from patients to assess the presence of acute GI GVHD versus infectious colitis.
• This finding supports the use of serum amphiregulin as a reliable diagnostic tool in managing acute GI GVHD, with implications for better clinical outcomes.